By Jason Derry —

NeuroMedix Inc., a biotechnology company seeking therapeutic
approaches for treating neuronal
diseases, has announced the intent to pursue
partners or acquisition possibilities.  The company currently has a potential product, Minozac, in pre-clinical
studies, and is preparing to submit the Phase I safety application for continuing
clinical trial progression.  Minozac is
NeuroMedix’s lead product for the treatment of Alzheimer’s disease and other
diseases of the central nervous system.  NeuroMedix has indicated that the intent to explore merger and
acquisition possibilities does not guarantee that such a relationship will be
formed.  A Fact Sheet discussing company
goals and providing additional information about Minozac in particular can be found here.

Jason Derry, Ph.D., who graduated with honors from DePaul University College of Law, is a molecular biologist and founding author of Patent Docs.